Dianthus Therapeutics, Inc.
DNTH
Jodie situation report
Dianthus Therapeutics, Inc.'s move is being confirmed by its market group.
DNTH accounts for 4.2% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for DNTH could be timestamped inside the aligned 5-minute window.
10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 5 disclosed connections are confirming.
- At least 11 of 16 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NBIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.
Who this business touches
The relationships behind DNTH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZBIOZenas BioPharma, Inc.partnerMay 5, 2026 ▾
“26 Licensing Agreements In June 2022, we executed a license agreement with Zenas BioPharma, Inc.”
WXILYFiling-linked namepartnerMar 9, 2026 ▾
“We work closely with our CDMO, WuXi Biologics, to ensure their suppliers have continuity of supply of raw and intermediate materials but cannot guarantee these efforts will always be successful.”
Depended on by
ANABAnaptysBio, Inc.competitorMar 3, 2026 ▾
“For our anti-BDCA2 program, our competitors include another anti-BDCA2 antibody, litifilimab (Biogen) in Phase 3 development for SLE and CLE, and a bispecific fusion protein targeting BDCA2 and BAFF/APRIL, DNTH212 (Dianthus Therapeutics) in Phase 1 developmen…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
DNTH is currently a Early Follower in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.